Search Bar & Filters
Found 102 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating BLU-5937, an oral drug, in adults with refractory chronic cough, including unexplained chronic cough, in a randomized, double-blind, placebo-controlled Phase 3 study. The main goal is to assess how BLU-5937 affects 24-hour cough frequency over 24 weeks. This study also monitors safety by tracking adverse events and changes in various health parameters during the treatment period. Participants are randomly assigned to one of three groups BLU-5937 25 mg twice daily, BLU-5937 50 mg twice daily, or a matching placebo taken twice daily. The treatment lasts for 24 weeks, and participants receive their assigned oral medication regularly throughout this time. The study uses a parallel-arm design and includes an extension in China. During the study, participants undergo assessments including cough frequency measurement, vital signs, blood tests for hormones and chemistry, hematology, and ECGs at baseline and Week 24. Researchers also evaluate cough severity and quality of life using questionnaires. Safety is closely monitored by recording adverse events, treatment discontinuations, and laboratory changes. The total participation duration is 24 weeks, with follow-up assessments at specified intervals.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable stage IIIII non-small cell lung cancer. This phase 2 clinical study involves patients eligible for curative surgery and aims to improve treatment outcomes using these combination therapies. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Participants are randomly assigned to one of two treatment groups. In the first group, patients receive 3 to 4 cycles of TQB2450 combined with chemotherapy every 21 days, followed by surgery 4 to 6 weeks after the last dose. TQB2450 treatment continues for one year after surgery. In the second group, participants receive 4 cycles of TQB2450 combined with 3 cycles of anlotinib hydrochloride capsule over 21-day cycles, followed by surgery 4 to 6 weeks after the last dose, with treatment continuing for one year starting 4 weeks after surgery. During the study, participants undergo tumor tissue testing for PD-L1 and regular assessments including measuring major pathologic response up to 60 months. Secondary outcomes include overall survival, event-free survival, disease-free survival, pathological complete response, and surgical outcomes, with follow-up extending up to 60 months. Patients are monitored for safety, treatment effects, and surgery timing. The total participation time may last several years to evaluate long-term results.
Actively Recruiting
This research aims to evaluate the effects of TQH3906 Capsules in adults with active Psoriatic Arthritis PsA. The study plans to enroll 156 participants to assess how different doses of TQH3906 compare to placebo in improving PsA symptoms at Week 12, focusing on the proportion of participants reaching a 20% improvement according to the American College of Rheumatology criteria. Participants will be randomly assigned to receive one of several oral treatments daily from Day 1 to Day 169. These include 24 mg or 16 mg doses of TQH3906 capsules, a placebo phase followed by TQH3906, or an active comparator, Tofacitinib Citrate tablets. The study uses a double-blind design to compare these treatments effects and safety. Throughout the study, participants will attend visits for assessments including the ACR improvement criteria at multiple time points up to Day 169. Blood samples will be collected to evaluate drug levels and immune markers, and safety will be monitored closely. The main outcome is the proportion of participants achieving ACR20 response at Week 12. The study duration extends up to November 2027, with detailed evaluations of drug effects and adverse events throughout.
Actively Recruiting
Researchers are evaluating the efficacy and safety of TQH3906, a Tyrosine Kinase 2 TYK2 inhibitor, in treating systemic lupus erythematosus SLE, an autoimmune disease. This randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial aims to assess how well TQH3906 works and its safety profile in adults diagnosed with SLE based on established criteria. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Participants are randomly assigned to one of three groups 16 mg TQH3906 capsule, 24 mg TQH3906 capsule, or placebo. All treatments are taken orally once daily for 48 weeks. The trial compares these doses to placebo to understand TQH3906s impact on disease activity. The study uses a parallel design and includes a quadruple masking method to keep participants and researchers unaware of group assignments. During the study, participants undergo regular assessments including clinical evaluation of disease activity using the Systemic Lupus Erythematosus Responder Index 4 SRI-4, lupus activity indices, and joint assessments up to week 48. Safety is monitored throughout, and background lupus medications must remain stable during the trial. The primary outcome measure is the percentage of participants achieving SRI-4 response by week 32, with additional secondary measures assessing remission, low disease activity, and symptom improvements. Participation lasts up to 48 weeks with scheduled visits and monitoring.
Actively Recruiting
Researchers are evaluating BG-C137, an antibody-drug conjugate targeting FGFR2b, in people with advanced solid tumors. This study aims to assess the safety, tolerability, how the drug moves and acts in the body, and early antitumor effects. It is a phase 1ab trial involving participants with tumors expressing FGFR2b or FGFR2 gene amplification who have received prior cancer treatments. The study is sponsored by BeOne Medicines and includes two main phases dose escalation and dose expansion. The trial has three parts Phase 1a evaluates increasing doses of BG-C137 alone and then in combination with other anticancer agents to establish safe dose levels. Phase 1b further explores the recommended dose in selected patient groups. BG-C137 and anticancer agents are given intravenously or orally depending on the treatment. Participants undergo dose escalation, safety expansions, and dose confirmations to determine the best dosing for further study. Participants will be monitored regularly for side effects and response to treatment for up to about two years. Assessments include measuring adverse events, drug levels in the blood, tumor response, and immune reactions to the drug. Safety follow-up visits occur after treatment ends. Researchers will measure outcomes such as maximum tolerated dose, overall response rate, disease control, and progression-free survival. The trial involves frequent visits for treatment and assessments throughout the study period.
Actively Recruiting
Researchers are evaluating the investigational drug HTD1801 to see if it can slow kidney damage progression in adults who have both Type 2 Diabetes T2DM and Chronic Kidney Disease CKD. The main focus is to determine if HTD1801 can reduce or limit the increase in urine albumin-to-creatinine ratio UACR compared to a placebo. This Phase 2 randomized, double-blind study aims to understand the drugs effect on kidney function decline in this population. Participants will be randomly assigned to take either HTD1801 capsules 1000mg as 4 capsules or matching placebo capsules twice daily for 12 weeks. The study involves weekly clinic visits for the first 4 weeks, followed by visits every 4 weeks, during which various assessments and check-ups are conducted. The study drug or placebo is taken orally, and safety is closely monitored through health reports and routine laboratory tests. During the study, participants will attend scheduled visits for assessments including urine and blood tests to measure kidney function and other health markers. The primary outcome measured is the relative change in UACR from baseline at 12 weeks. Secondary outcomes include changes in estimated glomerular filtration rate eGFR, albumin excretion rate, inflammatory markers, blood sugar levels, and cholesterol. Safety monitoring continues throughout the trial to track any health changes or adverse effects.
Actively Recruiting
Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and lasting effects of a single intravitreal injection of 4D-150 compared to aflibercept in adults with diabetic macular edema DME. The study is a Phase 3, randomized, double-masked, active-controlled trial designed to assess visual acuity changes and disease severity over one year. Participants will be randomly assigned to receive either a single dose of 4D-150 or aflibercept eye injections. The 4D-150 treatment is given once on Day 1, while aflibercept is administered at appropriate visits. The study lasts for 52 weeks, focusing on visual outcomes and the need for additional aflibercept injections after the initial treatments. Throughout the study, participants will undergo regular eye examinations to monitor visual acuity using the Early Treatment Diabetic Retinopathy Study ETDRS scale and assessments of diabetic retinopathy severity. Researchers will also track the number of aflibercept injections needed after Week 4. Safety and durability of the treatments will be closely observed during the one-year follow-up period.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and how the body processes INT-210 capsules in adults with active ulcerative colitis UC. This randomized, open-label study focuses on participants aged 18 to 75 years diagnosed with active UC, aiming to gather detailed information on the drugs pharmacokinetics and pharmacodynamics while monitoring treatment safety. Participants will receive oral INT-210 capsules in one of two doses 200 mg twice daily or 400 mg twice daily, starting from Day 1 of a 12-week treatment period. The study is designed to compare these two dosing regimens in parallel groups to assess their impact on UC symptoms and drug behavior in the body. During the study, participants will undergo various assessments including laboratory tests to monitor safety, clinical evaluations to measure remission and response rates, and pharmacokinetic sampling up to Day 85. Safety follow-up continues through Day 92 to track adverse events and important clinical parameters. Overall, participants can expect regular visits and monitoring throughout the treatment and follow-up phases lasting approximately 3 months.
1-10 of 102
1